GlassScriptPhysician profile
Timothy M Cullinane
NPI 1255376232
$20,473.34
in general payments reported to CMS, 2019-2025
36 companies · $3,393 in 2025
The $3,393 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,387 · 2020: $2,440 · 2021: $2,907 · 2022: $2,004 · 2023: $3,519 · 2024: $3,824 · 2025: $3,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $309.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,427.16 |
| Education | $309.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $2,732.29 | 2019-2025 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $2,311.97 | 2021-2025 | Vraylar |
| Otsuka America Pharmaceutical, INC. | $2,182.56 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,629.82 | 2020-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,279.86 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $1,222.79 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $1,135.63 | 2019-2025 | Invega Sustenna, Spravato, Invega |
| Allergan, INC. | $968.69 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $932.96 | 2019-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $889.67 | 2021-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $822.16 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $498.99 | 2019-2022 | |
| Almatica Pharma LLC | $454.01 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Axsome Therapeutics, INC. | $448.85 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $347.89 | 2021-2025 | Azstarys, Azstarys |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $329.25 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $316.17 | 2024-2025 | Cobenfy |
| Supernus Pharmaceuticals, INC. | $257.90 | 2021-2025 | Qelbree, Qelbree |
| Neos Therapeutics, LP | $240.72 | 2019-2025 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $225.43 | 2019-2023 | Jornay Pm |
| Eisai INC. | $201.19 | 2020-2021 | |
| Harmony Biosciences LLC | $193.43 | 2020-2022 | |
| Tris Pharma INC | $145.77 | 2023-2025 | Dyanavel Xr |
| Novo Nordisk INC | $145.40 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $113.39 | 2020-2022 | |
| Shire North American Group INC | $102.44 | 2019 | |
| Vertical Pharmaceuticals, LLC | $55.57 | 2019-2020 | |
| Noven Therapeutics, LLC | $50.04 | 2021-2024 | Secuado, Xelstrym |
| Idorsia Pharmaceuticals US INC | $47.69 | 2022-2025 | Quviviq |
| Owp Pharmaceuticals, INC. | $42.64 | 2019 | |
| Indivior INC. | $37.95 | 2022-2023 | Perseris |
| Avanir Pharmaceuticals, INC. | $36.21 | 2020-2021 | |
| Bausch Health US, LLC | $25.98 | 2019-2022 | |
| Uswm, LLC | $19.49 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.33 | 2021 | |
| Acadia Pharmaceuticals INC | $12.21 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Cullinane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.